(Q38398290)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Donald M Jensen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ira Jacobson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hiromitsu Kumada

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Joji Toyota

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jeong Heo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Boris Yoffe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

William Sievert

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Fernando Bessone

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Cheng-Yuan Peng

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Stuart K Roberts

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Youn-Jae Lee

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Rafia Bhore

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Patricia Mendez

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Eric Hughes

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Stephanie Noviello

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

1 reference

24 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

954-962

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology and genotype distribution of the hepatitis C virus infection

3 March 2020

cites work

1 reference

Hepatocellular carcinoma epidemiology

21 January 2018

1 reference

Novel therapies for hepatitis C - one pill fits all?

21 January 2018

1 reference

Racial differences in hepatitis C treatment eligibility

21 January 2018

1 reference

Future treatment of patients with HCV cirrhosis

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Strategies to manage hepatitis C virus (HCV) disease burden.

21 January 2018

1 reference

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting

21 January 2018

1 reference

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis

21 January 2018

1 reference

Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.

21 January 2018

1 reference

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting

21 January 2018

1 reference

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

21 January 2018

1 reference

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

21 January 2018

1 reference

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

21 January 2018

1 reference

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

21 January 2018

1 reference

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.

21 January 2018

1 reference

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

21 January 2018

1 reference

Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data

21 January 2018

1 reference

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms

21 January 2018

1 reference

Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review

21 January 2018

1 reference

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.

21 January 2018

1 reference

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.

21 January 2018

1 reference

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis

21 January 2018

1 reference

Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin

21 January 2018

1 reference

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

21 January 2018

1 reference

Hepatitis C virus infection in Taiwan: Past, present, and future

21 January 2018

1 reference

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.13049

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26683763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference